AmeriSource/Bergen FTC review
"The Federal Trade Commission's second request" on the proposed merger between AmeriSource and Bergen "is broad in nature and covers nearly all facets of the business of both companies," AmeriSource tells employees in a Q&A on the merger. In May, the two companies reported that FTC had requested additional information regarding the transaction, which would create the largest drug wholesaler (1"The Pink Sheet" May 14, In Brief)
You may also be interested in...
Federal Trade Commission requests additional information regarding proposed merger of AmeriSource and Bergen Brunswig, companies state May 7. The merger, announced March 19, would create the largest drug wholesaler (1"The Pink Sheet" March 26, p. 5)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials